BETHESDA, MdSpeakers at the National Institutes of Health
Consensus Development Conference on Adjuvant Therapy for Breast
Cancer will address the data on adjuvant chemotherapy, hormonal
therapy, and other aspects of postsurgical treatment. The 2½-day
meeting convenes on Nov. 1.
Following a day and a half of presentations, an independent,
nonfederal panel will weigh the evidence and prepare a conference
statement making recommendations for clinical practice. The seven
questions posed to the panel are:
Which factors should be used to select systemic adjuvant therapy?
For which patients should adjuvant hormonal therapy be recommended?
For which patients should adjuvant chemotherapy be
Which chemotherapy agents should be used and at what dose or
For which patients should postmas-tectomy radiotherapy be recommended?
How do side effects and quality-of-life issues factor into
individual decision-making about adjuvant therapy?
What are promising new research directions?
Patricia Eifel, MD, professor of radiation oncology, M.D. Anderson
Cancer Center, will chair the panel. The conferences major
sponsors are the NIH Office of Medical Applications of Research and
the National Cancer Institute.
Those interested in attending the conference can register on the
or by email (email@example.com).
Registration is free. The conference agenda can also be found at the
Additional information on the conference is available by calling